

DECLARATION OF CONFLICT OF INTEREST

Journal ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA

Supplement "Infections due to extended-spectrum betalactamase (ESBL)-producing microorganisms: an epidemiological and therapeutic challenge" Volume 25, Supplement 2, October 2007

Introduction

Ferran Navarro and
Jesús Rodríguez-Baño
Enferm Infecc Microbiol Clin.
2007;25 Supl 2:1

Conflict of interest:
Ferran Navarro declares he has
no conflict of interest.
Jesús Rodríguez-Baño declares he has
been a scientific advisor and speaker
for MSD, Wyeth, Roche and Pfizer.

Evolution and current situation of ESBL

Rafael Cantón, Aránzazu Valverde,
Ángela Novais, Fernando Baquero
and Teresa Coque
Enferm Infecc Microbiol Clin.
2007;25 Supl 2:2-10

Conflict of interest:
the authors declare they have
no conflict of interest.

The genetic environment of ESBL: implications in transmission

Ferran Navarro and Elisenda Miró
Enferm Infecc Microbiol Clin.
2007;25 Supl 2:11-7

Conflict of interest:
the authors declare they have
no conflict of interest.

Epidemiology and control of nosocomial ESBL-producing microorganisms

Carmen Peña and Miquel Pujol
Enferm Infecc Microbiol Clin.
2007;25 Supl 2:18-22

Conflict of interest:
the authors declare they have
no conflict of interest.

Epidemiology of ESBL in the community.

An increasing problem

Lorena López-Cerero and
Álvaro Pascual
Enferm Infecc Microbiol Clin.
2007;25 Supl 2:23-8

Conflict of interest:
Lorena López Cerero declares
she has no conflict of interest.
Álvaro Pascual declares
he has been a speaker
in a symposium organized
by AstraZeneca.

ESBL in animals and their importance in transmission to humans

Carmen Torres and
Myriam Zarazaga
Enferm Infecc Microbiol Clin.
2007;25 Supl 2:29-37

Conflict of interest:
the authors declare they have
no conflict of interest.

Association of ESBL with other resistance mechanisms

Luis Martínez-Martínez
Enferm Infecc Microbiol Clin.
2007;25 Supl 2:38-47

Conflict of interest:
the author declares he has
been a consultant for Wyeth,
participated in conferences
sponsored by Chiron, Wyeth
and GSK, and has received
research funds from Chiron,
Wyeth, GSK, MSD and Pfizer.

Importance of ESBL in the prognosis and cost of infections

José Miguel Cisneros and
Elisa Cordero
Enferm Infecc Microbiol Clin.
2007;25 Supl 2:48-53

Conflict of interest:
the authors declare they have
no conflict of interest.

Impact of ESBL on empirical therapy and antibiotic policies

Jesús Rodríguez-Baño and
María Dolores Navarro
Enferm Infecc Microbiol Clin.
2007;25 Supl 2:54-9

Conflict of interest:
Jesús Rodríguez-Baño declares
he has been a scientific advisor
and speaker for MSD, Wyeth,
Roche and Pfizer.
María Dolores Navarro declares
she has no conflict of interest.

Treatment of ESBL producers

David L. Paterson
Enferm Infecc Microbiol Clin.
2007;25 Supl 2:60-3

Conflict of interest:
the author has grants from the
Centers for Disease Control and
Prevention, National Institutes
of Health and AstraZeneca
Pharmaceuticals. He has been
a consultant to the following
companies: Acureon, Merck, Protez,
AstraZeneca, Elan, Johnson and
Johnson, and Rib-X.